Y Combinator · Aug 2024
YC publicly congratulated the team, restated the tissue-targeting thesis, and referenced investors including Y Combinator, Ethan Perlstein, and Oleksiy Ignatyev.
Enabling Tissue Targeting of Therapies
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Eugit Therapeutics is a San Carlos biotech developing TAGHOME, a tissue-targeting therapeutic platform that uses engineered gamma delta T cells and T-cell-receptor-based delivery to reduce toxicity and improve precision in inflammatory disease and cancer. Public company materials still list Nizar Batada as CEO/Co-Founder, Yoshinori Fukazawa as VP of Research/Co-Founder, and George Church as Scientific Advisor/Co-Founder, but their personal LinkedIn profiles indicate they have since moved to other roles, so current operating leadership is not fully transparent publicly.
Primary product
TAGHOME tissue-targeting drug-delivery / gamma delta T-cell platform
Founded
2022
Headquarters
San Carlos, California, United States
Team size
1-10 employees
Industry
Biotechnology Research
Sub-industry
Tissue-targeted immunotherapy / cell therapy
Offices
930 Brittan Ave, San Carlos, CA 94070-4002
Business model
therapeutics development
platform biotech
research partnerships / licensing
Funding
Stage
pre-seed + grant
Total raised
$775K
Latest round
SBIR Phase I grant · Aug 2024
Latest amount
$275K
Aug 2024 · National Science Foundation
Sep 2022 · Y Combinator
People & investors
Leadership
CEO / Co-Founder
VP of Research / Co-Founder
Scientific Advisor / Co-Founder
Work & culture
Product & market
Differentiators
- —Targets diseased tissue rather than relying on non-specific systemic delivery
- —Uses engineered gamma delta T cells and T-cell receptors for precision delivery
- —Positions therapies as off-the-shelf and infusion-ready
- —Built to reduce toxicity and clinical trial failures from non-specific drugs
- —Initial focus on inflammatory bowel disease with broader inflammatory-disease potential
Technology
TAGHOME tissue-targeting platform
gamma delta T cells
T-cell receptor-based targeting
computational genomics
immunology
synthetic biology
genome editing
gene engineering
off-the-shelf cell therapy
Customers
Patients with inflammatory bowel disease
Patients with tissue-specific inflammatory diseases
Patients with breast, ovarian, and prostate cancers
Competitors
Sana Biotechnology
BeiGene
Jazz Pharmaceuticals
Scale & contact
Estimated revenue
≈$330K ARR (public GetLatka estimate)
Latest news
Eugit Therapeutics · Aug 2024
Company announcement that Eugit received an NSF Phase 1 grant for tissue-targeting technology and thanked collaborators, investors, and NSF staff.
NSF SBIR · Aug 2024
Official NSF award page for the $275,000 Phase I grant to EUGIT THERAPEUTICS, INC. for targeted delivery payloads aimed at IBD.
Y Combinator
YC company profile describing TAGHOME, the IBD focus, and the company’s gamma delta T-cell-based therapeutic approach.
Jobs and careers at Eugit Therapeutics
0 jobs at Eugit Therapeutics
No open positions
Check back later for new openings